Nonetheless, the results of our study highlight an increased risk of ILD associated with ALK TKIs for the treatment of NSCLC and provide a better basis for understanding potential ILD associated with ALK TKIs, which helps clinicians pay attention to risk management. This evidence concerns the gene ALK and non-small cell lung carcinoma.